AR106018A1 - Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos - Google Patents
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicosInfo
- Publication number
- AR106018A1 AR106018A1 ARP160102593A ARP160102593A AR106018A1 AR 106018 A1 AR106018 A1 AR 106018A1 AR P160102593 A ARP160102593 A AR P160102593A AR P160102593 A ARP160102593 A AR P160102593A AR 106018 A1 AR106018 A1 AR 106018A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4alkyl
- independently selected
- 6alkyl
- halogen
- cyano
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente se relaciona con compuestos de la fórmula (1) o sales farmacéuticamente aceptables de los mismos, donde: Q¹ es C(R¹R¹); Q² es C(R²R²); Q³ es C(R³R³); X¹ es N y X² es CH; R¹, R¹, R², R², R³ y R³ se seleccionan independientemente entre hidrógeno, halógeno, hidroxilo, nitro, ciano, amino, C₁₋₆alquilo, C₂₋₆alquenilo, C₁₋₆alcoxi, C₂₋₆alquinilo, C₂₋₆alcanoilo, C₁₋₆tioalquilo, -C(O)OR⁹, -OC(O)R⁹, -NR⁹C(O)R¹⁰, -C(O)NR⁹R¹⁰, -OC(O)NR⁹R¹⁰, -NR⁹C(O)OR¹⁰, C₁₋₂haloalquilo, y C₁₋₂haloalcoxi; R⁹ y R¹⁰ se seleccionan independientemente, cada vez que aparecen, entre hidrógeno, C₁₋₆alquilo, (C₃₋₇cicloalquil)C₀₋₄alquilo, -C₀₋₄alquil(C₃₋₇cicloalquilo), y -O-C₀₋₄alquil(C₃₋₇cicloalquilo); o R¹ y R² se toman juntos para formar un anillo carbocíclico de 3 miembros; o R² y R³ se toman juntos para formar un anillo carbocíclico de 3 a 6 miembros; A es un grupo seleccionado entre los compuestos de fórmula (3) y (4); R⁵ y R⁶ se seleccionan independientemente entre -CHO, -C(O)NH₂, -C(O)NH(CH₃), C₂₋₆alcanoilo, hidrógeno, hidroxilo, halógeno, ciano, nitro, -COOH, -SO₂NH₂, vinilo, C₁₋₆alquilo, C₂₋₆alquenilo, C₁₋₆alcoxi, -C₀₋₄alquil(C₃₋₇cicloalquilo), -C(O)C₀₋₄alquil(C₃₋₇cicloalquilo), -P(O)(OR⁹)₂, -OC(O)R⁹, -C(O)OR⁹, -C(O)N(CH₂CH₂R⁹)(R¹⁰), -NR⁹C(O)R¹⁰, fenilo, y heteroarilo de 5 a 6 miembros; R⁸ y R⁸ se seleccionan independientemente entre hidrógeno, halógeno, hidroxilo, C₁₋₆alquilo, -C₀₋₄alquil(C₃₋₇cicloalquilo), C₁₋₆alcoxi, y (C₁₋₄alquilamino)C₀₋₂alquilo; o R⁸ y R⁸ se toman juntos para formar un grupo oxo; o R⁸ y R⁸ se pueden tomar junto con el átomo de carbono al cual están unidos para formar un anillo carbocíclico de 3 miembros; X¹¹ es N o CR¹¹; X¹² es CR¹²; X¹³ es CR¹³; X¹⁴ es N o CR¹⁴; uno de R¹² y R¹³ se selecciona entre R³¹, y el otro de R¹² y R¹³ se selecciona entre R³²; R³¹ se selecciona entre hidrógeno, halógeno, hidroxilo, nitro, ciano, amino, -COOH, C₁₋₂haloalquilo, C₁₋₂haloalcoxi, C₁₋₆alquilo, -C₀₋₄alquil(C₃₋₇cicloalquilo), C₂₋₆alquenilo, C₂₋₆alcanoilo, C₁₋₆alcoxi, C₂₋₆alqueniloxi, -C(O)OR⁹, C₁₋₆tioalquilo, -C₀₋₄alquilo-NR⁹R¹⁰, -C(O)NR⁹R¹⁰, -SO₂R⁹, -SO₂NR⁹R¹⁰, -OC(O)R⁹, y -C(NR⁹)NR⁹R¹⁰, en donde cada R³¹ distinto de hidrógeno, halógeno, hidroxilo, nitro, ciano, C₁₋₂haloalquilo, y C₁₋₂haloalcoxi no está sustituido o está sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, hidroxilo, nitro, ciano, amino, -COOH, -CONH₂, C₁₋₂haloalquilo, y C₁₋₂haloalcoxi, y cada R³¹ también está sustituido opcionalmente con un sustituyente seleccionado entre fenilo y heterociclo de 4 a 7 miembros que contiene 1, 2 ó 3 heteroátomos independientemente seleccionados entre N, O y S; en donde el fenilo o heterociclo de 4 a 7 miembros no está sustituido o está sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, hidroxilo, nitro, ciano, C₁₋₆alquilo, C₂₋₆alquenilo, C₂₋₆alcanoilo, C₁₋₆alcoxi, (mono y di-C₁₋₆alquilamino)C₀₋₄alquilo, C₁₋₆alquiléster, -(C₀₋₄alquil)(C₃₋₇cicloalquilo), C₁₋₂haloalquilo, y C₁₋₂haloalcoxi; R³² se selecciona entre: (i) un arilo seleccionado entre el grupo que consiste en fenilo y naftilo; o (ii) un heterociclo de 5 a 6 miembros saturado o insaturado que tiene 1, 2 ó 3 heteroátomos independientemente seleccionado entre N, O ó S, en donde el heterociclo es unido a través de un átomo de carbono en el anillo heterocíclico a un átomo de carbono del anillo A; o (iii) un heteroarilo seleccionado entre el grupo que consiste en piridinilo, pirimidinilo, pirazolilo, pirazinilo, furilo, tienilo, isoxazolilo, tiazolilo, oxadiazolilo, oxazolilo, isotiazol, quinolinilo, isoquinolinilo, benzofuranilo, cinolinilo, indolizinilo, flalazinilo, piridazinilo, triazinilo, pteridinilo, tiadiazolilo, furazanilo, benzofurazanilo, benzotiofenilo, benzotiazolilo, benzooxazolilo, quinazolinilo, quinoxalinilo, naftiridinilo, tetrahidrofuranilo y furopiridilo; en donde cada R³² puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, hidroxilo, amino, ciano, -CHO, -COOH, -CONH₂, C₁₋₆alquilo, C₂₋₆alquenilo, C₂₋₆alquinilo, -C₁₋₆alcoxi, C₂₋₆alcanoilo, C₁₋₆alquiléster, (mono y di-C₁₋₆alquilamino)C₀₋₂alquilo, C₁₋₂haloalquilo, hidroxi-C₁₋₆alquilo, éster, carbamato, urea, sulfonamida, -C₁₋₆alquil(heterociclo), C₁₋₆alquil(heteroarilo), -C₁₋₆alquil(C₃₋₇cicloalquilo), O-C₁₋₆alquil(C₃₋₇cicloalquilo), B(OH)₂, fosfato, fosfonato y C₁₋₂haloalcoxi; R¹¹ y R¹⁴ se seleccionan independientemente, cada vez que aparecen, entre hidrógeno, halógeno, hidroxilo, nitro, ciano, -O(PO)(OR⁹)₂, -(PO)(OR⁹)₂, C₁₋₆alquilo, C₂₋₆alquenilo, C₂₋₆alquinilo, C₂₋₆alcanoilo, C₁₋₆alcoxi, C₁₋₆tioalquilo, -C₀₋₄alquil(mono y di-C₁₋₆alquilamino), -C₀₋₄alquil(C₃₋₇cicloalquilo), -C₀₋₄alcoxi(C₃₋₇cicloalquilo), C₁₋₂haloalquilo, y C₁₋₂haloalcoxi; R²¹ y R²² se seleccionan independientemente, cada vez que aparecen, entre hidrógeno, hidroxilo, ciano, amino, C₁₋₆alquilo, C₁₋₆haloalquilo, C₁₋₆alcoxi, (C₃₋₇cicloalquil)C₀₋₄alquilo, (fenil)C₀₋₄alquilo, -C₁₋₄alquil-OC(O)OC₁₋₆alquilo, -C₁₋₄alquil-OC(O)C₁₋₆alquilo, -C₁₋₄alquil-C(O)OC₁₋₆alquilo, (heterocicloalquilo de 4 a 7 miembros)C₀₋₄alquilo que tiene 1, 2 ó 3 heteroátomos independientemente seleccionados entre N, O y S, y (heterociclo aromático o insaturado de 5 o 6 miembros)C₀₋₄alquilo que tiene 1, 2 ó 3 heteroátomos independientemente seleccionados entre N, O y S; R²³ se selecciona independientemente, cada vez que aparece, entre C₁₋₆alquilo, C₁₋₆haloalquilo, (aril)C₀₋₄alquilo, (C₃₋₇cicloalquil)C₀₋₄alquilo, (fenil)C₀₋₄alquilo, (heterocicloalquilo de 4 a 7 miembros)C₀₋₄alquilo que tiene 1, 2 ó 3 heteroátomos independientemente seleccionados entre N, O y S, y (heterociclo aromático o insaturado de 5 ó 6 miembros)C₀₋₄alquilo que tiene 1, 2 ó 3 heteroátomos independientemente seleccionados entre N, O y S; R²⁴ y R²⁵ se toman junto con el átomo de nitrógeno al cual están unidos para formar un grupo heterocicloalquilo monocíclico de 4 a 7 miembros, o un grupo heterocíclico bicíclico de 6 a 10 miembros que tiene anillos fusionados, espiro o en puente; L es un compuesto de fórmula (4); R¹⁷ es hidrógeno, C₁₋₆alquilo, o -C₀₋₄alquil(C₃₋₇cicloalquilo); R¹⁸ y R¹⁸ se seleccionan independientemente entre hidrógeno, halógeno, hidroximetilo, y metilo; m es 0, 1, 2 ó 3; B es un grupo carbocíclico monocíclico o bicíclico; un grupo carbocíclico-oxi monocíclico o bicíclico; un grupo heterocíclico monocíclico, bicíclico o tricíclico que tiene 1, 2, 3, ó 4 heteroátomos independientemente seleccionados entre N, O y S, y entre 4 a 7 átomos en el anillo por anillo; C₂₋₆alquenilo; C₂₋₆alquinilo; -(C₀₋₄alquil)(arilo); -(C₀₋₄alquil)(heteroarilo); o -(C₀₋₄alquil)(bifenilo), y B no está sustituido o está sustituido con uno o más sustituyentes seleccionados independientemente entre R³³ y R³⁴, y 0 ó 1 sustituyente seleccionado entre R³⁵ y R³⁶; R³³ se selecciona independientemente entre halógeno, hidroxilo, -COOH, ciano, C₁₋₆alquilo, C₂₋₆alcanoilo, C₁₋₆alcoxi, -C₀₋₄alquilo-NR⁹R¹⁰, -SO₂R⁹, C₁₋₂haloalquilo, y C₁₋₂haloalcoxi; R³⁴ se selecciona independientemente entre nitro, C₁₋₆alquenilo, C₂₋₆alquinilo, C₁₋₆tioalquilo, -JC₃₋₇cicloalquilo, -B(OH)₂, -JC(O)NR⁹R²³, -JOSO₂OR²¹, -C(O)(CH₂)₁₋₄S(O)R²¹, -O(CH₂)₁₋₄S(O)NR²¹R²², -JOP(O)(OR²¹)(OR²²), -JP(O)(OR²¹)(OR²²), -JOP(O)(OR²¹)R²², -JP(O)(OR²¹)R²², -JOP(O)R²¹R²², -JP(O)R²¹R²², -JSP(O)(OR²¹)(OR²²), -JSP(O)(OR²¹)(R²²), -JSP(O)(R²¹)(R²²), -JNR⁹P(O)(NHR²¹)(NHR²²), -JNR⁹P(O)(OR²¹)(NHR²²), -JNR⁹P(O)(OR²¹)(OR²²), -JC(S)R²¹, -JNR²¹SO₂R²², -JNR⁹S(O)NR¹⁰R²², -JNR⁹SO₂NR¹⁰R²², -JSO₂NR⁹COR²², -JSO₂NR⁹CONR²¹R²², JNR²¹SO₂R²², -JC(O)NR²¹SO₂R²², -JC(NH₂)NR²², -JC(NH₂)NR⁹S(O)₂R²², -JOC(O)NR²¹R²², -JNR²¹C(O)OR²², -JNR²¹OC(O)R²², -(CH₂)₁₋₄C₍O₎NR²¹R²², -JC(O)NR²⁴R²⁵, -JNR⁹C(O)R²¹, -JC(O)R²¹, -JNR⁹C(O)NR¹⁰R²², -CCR²¹, -(CH₂)₁₋₄OC(O)R²¹, y -JC(O)OR²³; en donde cada R³⁴ puede no estar sustituido o estar sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, hidroxilo, nitro, ciano, amino, oxo, -B(OH)₂, -Si(CH₃)₃, -COOH, -CONH₂, -P(O)(OH)₂, C₁₋₆alquilo, -C₀₋₄alquil(C₃₋₇cicloalquilo), C₁₋₆alcoxi, -C₀₋₂alquil(mono y di-C₁₋₄alquilamino), C₁₋₆alquiléster, C₁₋₄alquilamino, C₁₋₄hidroxiloalquilo, C₁₋₂haloalquilo, y C₁₋₂haloalcoxi; R³⁵ se selecciona independientemente entre naftilo, naftiloxi, indanilo, (heterocicloalquilo de 4 a 7 miembros)C₀₋₄alquilo que contiene 1 ó 2 heteroátomos seleccionados entre N, O y S, y heterociclo bicíclico que contiene 1, 2 ó 3 heteroátomos independientemente seleccionados entre N, O y S, y que contiene 4 a 7 átomos en cada anillo; en donde cada R³⁵ no está sustituido o está sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, hidroxilo, nitro, ciano, C₁₋₆alquilo, C₂₋₆alquenilo, C₂₋₆alcanoilo, C₁₋₆alcoxi, (mono y di-C₁₋₆alquilamino)C₀₋₄alquilo, C₁₋₆alquiléster, -C₀₋₄alquil(C₃₋₇cicloalquilo), -SO₂R⁹, C₁₋₂haloalquilo, y C₁₋₂haloalcoxi; R³⁶ se selecciona independientemente entre tetrazolilo, (fenil)C₀₋₂alquilo, (fenil)C₁₋₂alcoxi, fenoxi, y heteroarilo de 5 ó 6 miembros que contiene 1, 2 ó 3 heteroátomos independientemente seleccionados entre N, O, B y S, en donde cada R³⁶ no está sustituido o está sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, hidroxilo, nitro, ciano, C₁₋₆alquilo, C₂₋₆alquenilo, C₂₋₆alcanoilo, C₁₋₆alcoxi, (mono- y di-C₁₋₆alquilamino)C₀₋₄alquilo, C₁₋₆alquiléster, -C₀₋₄alquil(C₃₋₇cicloalquilo), -SO₂R⁹, -OSi(CH₃)₂C(CH₃)₃, -Si(CH₃)₂C(CH₃)₃, C₁₋₂haloalquilo, -S(O)₂R²¹, y C₁₋₂haloalcoxi; y J se selecciona independientemente, cada vez que aparece, entre un enlace covalente, C₁₋₄alquileno, -OC₁₋₄alquileno, C₂₋₄alquenileno, y C₂₋₄alquinileno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562209972P | 2015-08-26 | 2015-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106018A1 true AR106018A1 (es) | 2017-12-06 |
Family
ID=58100965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102593A AR106018A1 (es) | 2015-08-26 | 2016-08-24 | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
Country Status (23)
Country | Link |
---|---|
US (5) | US10011612B2 (es) |
EP (2) | EP3340981B1 (es) |
JP (3) | JP6877406B2 (es) |
KR (1) | KR20180043343A (es) |
CN (2) | CN114044800A (es) |
AR (1) | AR106018A1 (es) |
AU (2) | AU2016311425B2 (es) |
CA (1) | CA2996415A1 (es) |
DK (1) | DK3340981T3 (es) |
EA (2) | EA034781B1 (es) |
ES (1) | ES2935633T3 (es) |
FI (1) | FI3340981T3 (es) |
HK (1) | HK1257734A1 (es) |
HU (1) | HUE061088T2 (es) |
IL (2) | IL257175B (es) |
MX (2) | MX2018002399A (es) |
PL (1) | PL3340981T3 (es) |
PT (1) | PT3340981T (es) |
RU (1) | RU2743298C2 (es) |
SI (1) | SI3340981T1 (es) |
TW (1) | TW201722932A (es) |
WO (1) | WO2017035353A1 (es) |
ZA (1) | ZA201800641B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9796741B2 (en) | 2014-02-25 | 2017-10-24 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
WO2017035361A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
CN109310675A (zh) * | 2015-12-11 | 2019-02-05 | 莱福斯希医药公司 | 治疗性抑制化合物 |
WO2018160889A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
WO2018229543A2 (en) * | 2017-06-14 | 2018-12-20 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
US20190038623A1 (en) * | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
MA53095A (fr) | 2018-07-03 | 2021-05-12 | Ifm Due Inc | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
EP3841086A4 (en) * | 2018-08-20 | 2022-07-27 | Achillion Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D |
CA3111810A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of dancopan |
US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
KR20210093855A (ko) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 인자 d 억제제의 형태체 형태 |
WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
CN113195472A (zh) * | 2018-12-17 | 2021-07-30 | 艾其林医药公司 | 用于治疗补体介导的病症的靶向给药 |
WO2021067801A1 (en) * | 2019-10-03 | 2021-04-08 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
WO2021183555A1 (en) * | 2020-03-10 | 2021-09-16 | Achillion Pharmaceuticals, Inc. | Ocular drug depot for complement-mediated disorders |
WO2022047128A2 (en) * | 2020-08-28 | 2022-03-03 | Alexion Pharmaceuticals, Inc. | Method for treating complement mediated disorders caused by betacoronaviruses |
CN112375027B (zh) * | 2020-12-07 | 2023-03-31 | 中国药科大学 | 吲哚磺酰胺类衍生物及其医药用途 |
US11478484B2 (en) * | 2021-03-26 | 2022-10-25 | Consortium “Ukrindustry” | Method for preparing a liposomal composition comprising latanoprost, and the pharmacologically active liposomal composition for ophthalmotherapy prepared by this method |
WO2023023227A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors |
CA3234428A1 (en) * | 2021-10-18 | 2023-04-27 | Nader Najafian | Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy |
CN114437043B (zh) * | 2022-02-02 | 2023-06-16 | 浙江乐普药业股份有限公司 | 一种抗新冠药物Nirmatrelvir的制备方法 |
WO2024008121A1 (zh) * | 2022-07-06 | 2024-01-11 | 南京明德新药研发有限公司 | 二氟取代的氮杂双环化合物及其应用 |
Family Cites Families (238)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB929401A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Encapsulated emulsions and processes for their preparation |
GB929405A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Processes for the encapsulation of particles |
GB969808A (en) | 1962-06-08 | 1964-09-16 | Boots Pure Drug Co Ltd | Anthelmintic compositions and compounds |
IT1148784B (it) | 1980-04-09 | 1986-12-03 | Eurand Spa | Procedimento per la preparazione di microcapsule in un veicolo liquido |
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
JP2528706B2 (ja) | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5013557A (en) | 1989-10-03 | 1991-05-07 | Warner-Lambert Company | Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same |
KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
TW209174B (es) | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
AU4198793A (en) | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
SE9401108D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
EP0797987B1 (en) | 1994-12-19 | 2003-10-15 | Daiichi Pharmaceutical Co., Ltd. | Sustained-release granular preparation and process for producing the same |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
DK0784974T3 (da) | 1995-07-26 | 2003-09-01 | Kyowa Hakko Kogyo Kk | Fremstilling af xanthinderivater i fast dispersion |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
ATE238068T1 (de) | 1996-07-01 | 2003-05-15 | Univ Utrecht | Hydrolysierbare hydrogele zur gesteuerten freisetzung |
EP0842657A1 (en) | 1996-11-19 | 1998-05-20 | OctoPlus B.V. | Microspheres for controlled release and processes to prepare these microspheres |
US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
WO1998055471A1 (en) | 1997-06-03 | 1998-12-10 | Biocryst Pharmaceuticals, Inc. | Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
CA2325638A1 (en) * | 1998-03-26 | 1999-09-30 | Hideki Yamada | Amide derivatives and nociceptin antagonists |
WO2000014095A1 (en) | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
GB9827145D0 (en) | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
AU6868900A (en) | 1999-09-03 | 2001-04-10 | Ajinomoto Co., Inc. | Novel processes for preparing oxazepine derivatives |
GB9927011D0 (en) | 1999-11-16 | 2000-01-12 | Advanced Phytonics Ltd | Method for the production of particles |
CA2395129C (en) | 1999-12-20 | 2008-12-16 | Nicholas J. Kerkhof | Process for producing nanometer particles by fluid bed spray-drying |
SI1242055T1 (sl) | 1999-12-23 | 2008-08-31 | Pfizer Prod Inc | S hidrogelom prenašana odmerna oblika zdravila |
EE200200357A (et) | 1999-12-23 | 2003-10-15 | Pfizer Products Inc. | Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid |
AU2001247244B2 (en) | 2000-02-28 | 2005-06-02 | Genesegues, Inc. | Nanocapsule encapsulation system and method |
US7455855B2 (en) | 2000-04-03 | 2008-11-25 | Santen Pharmaceutical Co., Ltd. | Delivering substance and drug delivery system using the same |
GB0009469D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
ES2632461T3 (es) | 2000-06-27 | 2017-09-13 | Vectura Limited | Formulaciones para su uso en dispositivos inhaladores |
GB2364919A (en) | 2000-07-21 | 2002-02-13 | Cambridge Consultants | Inhalers |
GB0021024D0 (en) | 2000-08-29 | 2000-10-11 | Glaxo Group Ltd | Inhalation device |
JP2004534721A (ja) | 2000-10-31 | 2004-11-18 | ピーアール ファーマシューティカルズ,インク. | 生理活性分子の向上した送達のための方法及び組成物 |
WO2002043700A2 (en) | 2000-11-30 | 2002-06-06 | Vectura Limited | Particles for use in a pharmaceutical composition |
US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
US7528165B2 (en) * | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
MXPA04007428A (es) | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido. |
NZ537853A (en) | 2002-07-16 | 2007-02-23 | Amura Therapeutics Ltd | Inhibitors of cathepsin K and related cysteine protesases of the CA clan |
AU2003302084A1 (en) | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
US7431026B2 (en) * | 2003-04-22 | 2008-10-07 | Avalon Advanced Products, Inc | Paintball refillers and method for making and using same |
AU2003902946A0 (en) | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
CA2538997A1 (en) | 2003-09-15 | 2005-03-24 | Vectura Limited | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
JP2007505932A (ja) | 2003-09-18 | 2007-03-15 | マクサイト, インコーポレイテッド | 経強膜送達 |
WO2005030822A2 (en) | 2003-09-23 | 2005-04-07 | University Of North Carolina At Chapel Hill | Photocurable perfluoropolyethers for use as novel materials in microfluidic devices |
SE0302665D0 (sv) | 2003-10-07 | 2003-10-07 | Astrazeneca Ab | Novel Process |
WO2005044186A2 (en) | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same |
DK1704585T3 (en) | 2003-12-19 | 2017-05-22 | Univ North Carolina Chapel Hill | Methods for preparing isolated micro- and nanostructures using soft lithography or printing lithography |
WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
CA2560653C (en) | 2004-03-24 | 2013-08-06 | Jerini Ag | Angiogenesis inhibitors and uses thereof |
GB0407627D0 (en) | 2004-04-02 | 2004-05-05 | Vectura Ltd | Corkscrew pump |
US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
WO2006012373A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
PL370285A1 (pl) | 2004-09-23 | 2006-04-03 | Glaxosmithkline Pharmaceuticals Spółka Akcyjna | Inhalator proszkowy |
US9265731B2 (en) | 2005-01-28 | 2016-02-23 | Bend Research, Inc. | Drying of drug-containing particles |
US8617604B2 (en) | 2005-02-03 | 2013-12-31 | Bend Research, Inc. | Pharmaceutical compositions with enhanced performance |
JP2008530127A (ja) | 2005-02-09 | 2008-08-07 | マクサイト, インコーポレイテッド | 眼の処置のための処方物 |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
EP1904932A4 (en) | 2005-06-17 | 2013-02-27 | Univ North Carolina | METHODS, SYSTEMS AND MATERIALS FOR MANUFACTURING NANOPARTICLES |
EP2537657A3 (en) | 2005-08-09 | 2016-05-04 | The University of North Carolina At Chapel Hill | Methods and materials for fabricating microfluidic devices |
US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
WO2007056561A2 (en) | 2005-11-09 | 2007-05-18 | Liquidia Technologies, Inc. | Medical device, materials, and methods |
US20070149593A1 (en) | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US8944804B2 (en) | 2006-01-04 | 2015-02-03 | Liquidia Technologies, Inc. | Nanostructured surfaces for biomedical/biomaterial applications and processes thereof |
JP5819579B2 (ja) | 2006-01-13 | 2015-11-24 | サーモディクス,インコーポレイティド | 薬物送達のためのマトリックスを含む微粒子 |
WO2007112052A2 (en) | 2006-03-23 | 2007-10-04 | Macusight, Inc. | Formulations and methods for vascular permeability-related diseases or conditions |
US20080166411A1 (en) | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
US20100003291A1 (en) | 2006-05-15 | 2010-01-07 | Liquidia Technologies, Inc. | Nano-particles for cosmetic applications |
UA101468C2 (ru) * | 2006-07-13 | 2013-04-10 | Ачілліон Фармасьютікалз, Інк. | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации |
WO2008013952A2 (en) | 2006-07-27 | 2008-01-31 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells |
GB0617480D0 (en) | 2006-09-06 | 2006-10-18 | Univ Sheffield | Novel nanoparticles |
ES2360538T3 (es) | 2006-09-08 | 2011-06-06 | Johns Hopkins University | Composiciones para aumentar el transporte a través de moco. |
US9022970B2 (en) | 2006-10-16 | 2015-05-05 | Alcon Research, Ltd. | Ophthalmic injection device including dosage control device |
WO2008047831A1 (fr) | 2006-10-17 | 2008-04-24 | Kyowa Hakko Kirin Co., Ltd. | Inhibiteurs de JAK |
AR063621A1 (es) | 2006-11-09 | 2009-02-04 | Alcon Res Ltd | Matriz polimerica insoluble en agua para la administracion de farmacos |
WO2008100304A2 (en) | 2006-11-15 | 2008-08-21 | The University Of North Carolina At Chapel Hill | Polymer particle composite having high fidelity order, size, and shape particles |
US8193237B2 (en) | 2007-01-15 | 2012-06-05 | Santen Pharmaceutical Co., Ltd. | Indole derivative having IκB kinase β inhibitory activity |
MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
US20090203709A1 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
US9943401B2 (en) | 2008-04-04 | 2018-04-17 | Eugene de Juan, Jr. | Therapeutic device for pain management and vision |
WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
US8945527B2 (en) | 2008-04-25 | 2015-02-03 | The University Of North Carolina At Chapel Hill | Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates |
WO2010009087A1 (en) | 2008-07-15 | 2010-01-21 | Eyegate Pharmaceuticals, Inc. | Iontophoretic delivery of a controlled-release formulation in the eye |
AU2009302956B8 (en) | 2008-10-08 | 2012-09-27 | Astrazeneca Ab | Inhalation device and method of dispensing medicament |
KR101880582B1 (ko) | 2008-12-05 | 2018-07-20 | 리퀴디아 테크놀로지스 인코포레이티드 | 패턴 재료 제조 방법 |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
PL2391419T3 (pl) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Dostarczanie leku do tylnego odcinka |
US20120052041A1 (en) | 2009-02-04 | 2012-03-01 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
JP5969212B2 (ja) | 2009-02-10 | 2016-08-17 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us,Inc. | 眼用トロカール組立体 |
KR101674904B1 (ko) | 2009-02-26 | 2016-11-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 중재형 약물전달 시스템과 그 방법 |
US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
AU2010256558B2 (en) | 2009-06-03 | 2013-10-03 | Forsight Labs, Llc | Anterior segment drug delivery |
US20120114554A1 (en) | 2009-07-13 | 2012-05-10 | Liquidia Technologies, Inc. | Engineered Aerosol Particles, And Associated Methods |
TWI492769B (zh) | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
US8410139B2 (en) * | 2009-10-07 | 2013-04-02 | Bristol-Myers Squibb Company | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
EP2490026A4 (en) | 2009-10-16 | 2013-08-21 | Mochida Pharm Co Ltd | MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE |
US20130066283A1 (en) | 2009-10-23 | 2013-03-14 | Nexisvision, Inc. | Corneal Denervation for Treatment of Ocular Pain |
WO2011050365A1 (en) | 2009-10-23 | 2011-04-28 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
TWI478730B (zh) | 2009-12-03 | 2015-04-01 | Alcon Res Ltd | 眼科乳劑 |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
WO2011109384A2 (en) | 2010-03-02 | 2011-09-09 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
MX337548B (es) | 2010-04-16 | 2016-03-10 | Ac Immune Sa | Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide. |
KR20180001587A (ko) | 2010-05-05 | 2018-01-04 | 알콘 리서치, 리미티드 | 안정화된 안과용 갈락토만난 제제 |
WO2011153349A1 (en) | 2010-06-02 | 2011-12-08 | Alcon Research, Ltd. | Ophthalmic compositions comprising pbo-peo-pbo block copolymers |
CA2807537C (en) | 2010-08-05 | 2018-09-18 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
WO2012019047A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Subconjunctival implant for posterior segment drug delivery |
WO2012019136A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
EP3960134A1 (en) | 2010-08-05 | 2022-03-02 | ForSight Vision4, Inc. | Implantable therapeutic device |
PT2611529T (pt) | 2010-09-03 | 2019-05-09 | Bend Res Inc | Método de secagem por pulverização |
US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
US20120121718A1 (en) | 2010-11-05 | 2012-05-17 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
WO2012065006A2 (en) | 2010-11-11 | 2012-05-18 | Forsight Vision4, Inc. | Methods and apparatus to determine porous structures for drug delivery |
TW201304822A (zh) | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
CN103402996B (zh) | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
WO2012145801A1 (en) | 2011-04-29 | 2012-11-01 | Jagat Rakesh Kanwar | Nanoparticle |
US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
US8809313B2 (en) * | 2011-05-27 | 2014-08-19 | Achillion Pharmaceuticals, Inc. | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections |
WO2012177782A1 (en) | 2011-06-20 | 2012-12-27 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
AU2012272706B2 (en) | 2011-06-22 | 2017-07-06 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
GB201115874D0 (en) | 2011-09-14 | 2011-10-26 | Astrazeneca Ab | Inhaler |
AU2012308317B2 (en) | 2011-09-14 | 2017-01-05 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
PT2755600T (pt) | 2011-09-16 | 2021-04-19 | Forsight Vision4 Inc | Aparelhos de troca de fluidos |
EP2785326A2 (en) | 2011-11-29 | 2014-10-08 | The University of North Carolina at Chapel Hill | Geometrically engineered particles and methods for modulating macrophage or immune responses |
CA2859046C (en) | 2011-12-14 | 2019-10-22 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
US10046121B2 (en) | 2011-12-27 | 2018-08-14 | Vectura Gmbh | Inhalation device with feedback system |
EP2724741B1 (en) | 2012-10-26 | 2017-06-14 | Vectura GmbH | Inhalation device for use in aerosol therapy |
CA2863632C (en) | 2012-01-19 | 2017-07-11 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
KR101903028B1 (ko) | 2012-03-09 | 2018-10-02 | 벡투라 게엠베하 | 흡입 장치용 혼합 채널 및 흡입 장치 |
US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
US8962577B2 (en) | 2012-03-16 | 2015-02-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
US20140107025A1 (en) | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
KR102154880B1 (ko) | 2012-05-03 | 2020-09-10 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
WO2013166436A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
AP2014008040A0 (en) | 2012-05-04 | 2014-10-31 | Novartis Ag | Complement pathway modulators and uses thereof |
JP6392209B2 (ja) | 2012-05-04 | 2018-09-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
KR102339315B1 (ko) * | 2012-06-18 | 2021-12-15 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
ES2584702T3 (es) | 2012-06-20 | 2016-09-28 | Novartis Ag | Moduladores de ruta del complemento y usos de los mismos |
JP6154897B2 (ja) * | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
US9388199B2 (en) | 2012-06-28 | 2016-07-12 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
US20150191462A1 (en) * | 2012-06-28 | 2015-07-09 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
EP2867227B1 (en) | 2012-06-28 | 2018-11-21 | Novartis AG | Complement pathway modulators and uses thereof |
US9468661B2 (en) * | 2012-06-28 | 2016-10-18 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
EP2867226B1 (en) | 2012-06-28 | 2018-11-14 | Novartis AG | Complement pathway modulators and uses thereof |
WO2014002059A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Ag | CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide |
WO2014005150A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Ag | Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof |
WO2014009833A2 (en) | 2012-07-12 | 2014-01-16 | Novartis Ag | Complement pathway modulators and uses thereof |
ES1077714Y (es) | 2012-07-31 | 2012-12-20 | Gutierrez Jose Ramon Perez | Envase de madera |
WO2014037480A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
CA2885022A1 (en) | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
AU2013317899A1 (en) | 2012-09-20 | 2015-05-07 | Akina, Inc. | Biodegradable microcapsules containing filling material |
WO2014066775A1 (en) | 2012-10-26 | 2014-05-01 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
US9773428B2 (en) | 2012-12-11 | 2017-09-26 | Fluidity Software, Inc. | Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems |
EP2948480A4 (en) | 2013-01-23 | 2016-12-07 | Musc Found For Res Dev | NATURAL ANTIBODY TARGETING CONSTRUCTS AND USES THEREOF |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
ES2834964T3 (es) | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
JP2016169161A (ja) | 2013-07-19 | 2016-09-23 | 大日本住友製薬株式会社 | 新規イミダゾピリジン化合物 |
AU2014334636A1 (en) | 2013-10-15 | 2016-06-02 | Forsight Vision5, Inc. | Formulations and methods for increasing or reducing mucus |
JP2016535042A (ja) | 2013-10-30 | 2016-11-10 | ノバルティス アーゲー | 2−ベンジル−ベンゾイミダゾール補体因子b阻害剤およびその使用 |
WO2015085251A1 (en) | 2013-12-06 | 2015-06-11 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
US9796741B2 (en) | 2014-02-25 | 2017-10-24 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2017035411A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of immune and inflammatory disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
WO2017035417A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of immune and inflammatory disorders |
EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
WO2017035415A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of immune and inflammatory disorders |
WO2017035348A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of medical disorders |
WO2017035418A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
WO2017035413A2 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
WO2017035352A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of medical disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
CN109310675A (zh) | 2015-12-11 | 2019-02-05 | 莱福斯希医药公司 | 治疗性抑制化合物 |
TWI747873B (zh) | 2016-02-01 | 2021-12-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
CN112280762B (zh) * | 2020-11-13 | 2022-11-01 | 中山俊凯生物技术开发有限公司 | 一种烟酰胺核糖激酶突变体及其编码基因和应用 |
CN113832125B (zh) * | 2021-10-19 | 2023-09-26 | 中山百灵生物技术股份有限公司 | 一种烟酰胺核糖激酶突变体及其编码基因和应用 |
CN114107160A (zh) * | 2021-12-27 | 2022-03-01 | 浙江工业大学 | 一种烟酰胺核糖激酶基因工程菌及其应用 |
CN114606213A (zh) * | 2022-01-28 | 2022-06-10 | 浙江工业大学 | 一种多聚磷酸激酶突变体、工程菌及其应用 |
-
2016
- 2016-08-24 AR ARP160102593A patent/AR106018A1/es unknown
- 2016-08-25 PT PT168401214T patent/PT3340981T/pt unknown
- 2016-08-25 CA CA2996415A patent/CA2996415A1/en active Pending
- 2016-08-25 EA EA201890594A patent/EA034781B1/ru unknown
- 2016-08-25 US US15/247,399 patent/US10011612B2/en active Active
- 2016-08-25 EP EP16840121.4A patent/EP3340981B1/en active Active
- 2016-08-25 MX MX2018002399A patent/MX2018002399A/es unknown
- 2016-08-25 CN CN202111364018.6A patent/CN114044800A/zh active Pending
- 2016-08-25 EA EA201992884A patent/EA201992884A3/ru unknown
- 2016-08-25 HU HUE16840121A patent/HUE061088T2/hu unknown
- 2016-08-25 IL IL257175A patent/IL257175B/en unknown
- 2016-08-25 AU AU2016311425A patent/AU2016311425B2/en active Active
- 2016-08-25 SI SI201631646T patent/SI3340981T1/sl unknown
- 2016-08-25 PL PL16840121.4T patent/PL3340981T3/pl unknown
- 2016-08-25 RU RU2018110647A patent/RU2743298C2/ru active
- 2016-08-25 ES ES16840121T patent/ES2935633T3/es active Active
- 2016-08-25 IL IL295844A patent/IL295844A/en unknown
- 2016-08-25 CN CN201680049237.6A patent/CN108024992A/zh active Pending
- 2016-08-25 FI FIEP16840121.4T patent/FI3340981T3/fi active
- 2016-08-25 KR KR1020187008276A patent/KR20180043343A/ko active IP Right Grant
- 2016-08-25 DK DK16840121.4T patent/DK3340981T3/da active
- 2016-08-25 EP EP22166051.7A patent/EP4053117A1/en active Pending
- 2016-08-25 WO PCT/US2016/048696 patent/WO2017035353A1/en active Application Filing
- 2016-08-25 JP JP2018510097A patent/JP6877406B2/ja active Active
- 2016-08-26 TW TW105127598A patent/TW201722932A/zh unknown
-
2018
- 2018-01-30 ZA ZA2018/00641A patent/ZA201800641B/en unknown
- 2018-02-26 MX MX2022011029A patent/MX2022011029A/es unknown
- 2018-06-15 US US16/010,081 patent/US10287301B2/en active Active
-
2019
- 2019-01-03 HK HK19100108.8A patent/HK1257734A1/zh unknown
- 2019-03-12 US US16/351,203 patent/US10822352B2/en active Active
-
2020
- 2020-09-09 US US17/015,171 patent/US20210269458A1/en not_active Abandoned
-
2021
- 2021-04-27 JP JP2021075348A patent/JP7210637B2/ja active Active
- 2021-04-30 AU AU2021202728A patent/AU2021202728B2/en active Active
-
2023
- 2023-01-11 JP JP2023002028A patent/JP2023052297A/ja active Pending
- 2023-03-21 US US18/124,427 patent/US20230287005A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106018A1 (es) | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos | |
AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
AR105102A1 (es) | Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR097633A1 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
AR104720A1 (es) | Moduladores de ccr2 | |
AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
AR093308A1 (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
AR094174A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
AR076550A1 (es) | Inhibidores de la janus tirosina kinasa (jak) | |
AR088014A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR117544A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
AR108185A1 (es) | Amidas terciarias y método para su uso | |
AR098492A1 (es) | Derivados de purina | |
AR114828A1 (es) | Compuestos de pteridinona y sus usos | |
AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
AR094852A1 (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
AR097435A1 (es) | 6-alquinilpiridinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |